Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Recurrence 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1

Interventions

Temozolomide 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Paclitaxel 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cognitive Behavioral Therapy 2Blood Specimen Collection 2Azacitidine 2vocimagene amiretrorepvec 1trametinib 1sonidegib 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1repotrectinib 1imetelstat 1fludarabine 1epacadostat 1dostarlimab 1depatuxizumab 1ceritinib 1cemiplimab 1cc-486 1carboxyamido-triazole 1acalabrutinib 1abiraterone 1Uncertainty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × acalabrutinib × Lymphoid × Clear all
NCT02586857 2026-03-25

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Acerta Pharma BV

Phase 1/2 Active not recruiting
24 enrolled 10 charts
CNSLymphoidOther hematologic neoplasm

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡